Thermo Fisher Scientific
US.TMO
613.78
-4.65
-0.75%
Thermo Fisher Scientific
613.78
-4.65
-0.75%
Collector offline (last heartbeat: 19122s ago)
· 2026-09-04 20:02
Pre-market
605.71
-2.06%
After-hours
613.78
0.00%
Revenue annual, last 8 years
Latest year +3.91% YoY
Margins
- Gross margin
- 40.93%
- Operating margin
- 18.20%
- Net margin
- 15.05%
Key ratios & quality
- Enterprise value
- 256.22B
- Altman Z-Score
- 3.94
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.94, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.36B | 25.54B | 32.22B | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B |
| Gross profit | 10.86B | 11.33B | 16.00B | 19.64B | 18.97B | 17.10B | 17.70B | 18.24B |
| Selling & admin expenses | 6.06B | 6.14B | 6.93B | 8.01B | 8.99B | 8.45B | 8.60B | 8.73B |
| Research & development | 967.00M | 1.00B | 1.18B | 1.41B | 1.47B | 1.34B | 1.39B | 1.40B |
| Operating profit | 3.83B | 4.18B | 7.89B | 10.23B | 8.51B | 7.32B | 7.72B | 8.11B |
| Pretax profit | 3.26B | 4.07B | 7.23B | 8.84B | 7.84B | 6.30B | 7.04B | 7.31B |
| Tax | 324.00M | 374.00M | 850.00M | 1.11B | 703.00M | 284.00M | 657.00M | 547.00M |
| Net profit | 2.94B | 3.70B | 6.38B | 7.73B | 6.96B | 5.96B | 6.34B | 6.72B |
| Basic EPS | 7 | 9 | 16 | 20 | 18 | 16 | 17 | 18 |
| Diluted EPS | 7.24 | 9.17 | 15.96 | 19.46 | 17.63 | 15.45 | 16.53 | 17.74 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 10.36B | 10.86B | 11.12B | 12.22B | 11.01B | 11.99B |
| Gross profit | 4.24B | 4.41B | 4.58B | 5.01B | 4.43B | 4.88B |
| Selling & admin expenses | 2.08B | 2.14B | 2.16B | 2.35B | 2.18B | 2.33B |
| Research & development | 342.00M | 352.00M | 346.00M | 356.00M | 336.00M | 364.00M |
| Operating profit | 1.82B | 1.92B | 2.08B | 2.30B | 1.91B | 2.19B |
| Pretax profit | 1.62B | 1.71B | 1.83B | 2.15B | 1.73B | 1.92B |
| Tax | 95.00M | 92.00M | 207.00M | 153.00M | 70.00M | 167.00M |
| Net profit | 1.51B | 1.62B | 1.62B | 1.97B | 1.66B | 1.74B |
| Basic EPS | 4 | 4 | 4 | 5 | 4 | 5 |
| Diluted EPS | 3.98 | 4.28 | 4.27 | 5.21 | 4.43 | 4.68 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 10.63B | 11.89B | 21.96B | 20.11B | 25.23B | 24.59B | 22.14B | 28.71B |
| Cash & ST investments | 2.10B | 2.40B | 10.33B | 4.48B | 8.52B | 8.08B | 5.57B | 10.11B |
| Inventory | 3.01B | 3.37B | 4.03B | 5.05B | 5.63B | 5.09B | 4.98B | 5.43B |
| Total assets | 56.23B | 58.38B | 69.05B | 95.12B | 97.15B | 98.73B | 97.32B | 110.34B |
| Total current liabilities | 6.15B | 6.20B | 10.30B | 13.44B | 17.01B | 14.01B | 13.33B | 15.19B |
| Short-term debt | 1.27B | 676.00M | 2.63B | 2.54B | 5.58B | 3.61B | 2.21B | 3.53B |
| Long-term debt | 17.72B | 17.08B | 19.11B | 32.33B | 28.91B | 31.31B | 29.06B | 35.85B |
| Total liabilities | 28,646,000,000.00 | 28,706,000,000.00 | 34,535,000,000.00 | 54,146,000,000.00 | 53,006,000,000.00 | 51,884,000,000.00 | 47,649,000,000.00 | 56,807,000,000.00 |
| Total equity | 27.59B | 29.68B | 34.52B | 40.98B | 44.15B | 46.84B | 49.67B | 53.54B |
| Retained earnings | 18.70B | 22.09B | 28.12B | 35.43B | 41.91B | 47.36B | 53.10B | 59.16B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 23.38B | 24.58B | 22.30B | 28.71B | 22.32B | 23.37B |
| Cash & ST investments | 5.95B | 6.39B | 3.55B | 10.11B | 3.26B | 4.06B |
| Inventory | 5.22B | 5.56B | 5.75B | 5.43B | 5.50B | 5.63B |
| Total assets | 99.04B | 101.23B | 103.02B | 110.34B | 113.28B | 113.17B |
| Total current liabilities | 13.17B | 12.72B | 14.89B | 15.19B | 14.62B | 15.07B |
| Short-term debt | 2.82B | 2.21B | 3.82B | 3.53B | 3.09B | 3.37B |
| Long-term debt | 31.37B | 33.02B | 31.86B | 35.85B | 40.07B | 39.18B |
| Total liabilities | 49,556,000,000.00 | 50,628,000,000.00 | 51,866,000,000.00 | 56,807,000,000.00 | 61,220,000,000.00 | 60,366,000,000.00 |
| Total equity | 49.49B | 50.60B | 51.15B | 53.54B | 52.06B | 52.81B |
| Retained earnings | 54.45B | 55.90B | 57.35B | 59.16B | 60.63B | 62.19B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.54B | 4.97B | 8.29B | 9.31B | 9.15B | 8.41B | 8.67B | 7.82B |
| Depreciation & amortization | 2.27B | 2.28B | 2.33B | 2.59B | 3.38B | 3.41B | 3.11B | 2.78B |
| Free cash flow | 3.79B | 4.05B | 6.82B | 6.79B | 6.91B | 6.93B | 7.27B | 6.29B |
| Dividends paid | -266.00M | -297.00M | -337.00M | -395.00M | -455.00M | -523.00M | -583.00M | -636.00M |
| Stock buybacks / issuance | -500.00M | -1.50B | -1.50B | -2.00B | -3.00B | -3.00B | -4.00B | -3.00B |
| Ending cash balance | 2.12B | 2.42B | 10.34B | 4.49B | 8.54B | 8.10B | 4.04B | 9.88B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 723.00M | 1.40B | 2.24B | 3.46B | 1.19B | 2.13B |
| Depreciation & amortization | 705.00M | 686.00M | 661.00M | 728.00M | 736.00M | 817.00M |
| Free cash flow | 361.00M | 1.11B | 1.84B | 2.99B | 816.00M | 1.68B |
| Dividends paid | -149.00M | -162.00M | -163.00M | -162.00M | -162.00M | -175.00M |
| Stock buybacks / issuance | -2.00B | 0 | -963.00M | -37.00M | -3.00B | -1.00B |
| Ending cash balance | 4.17B | 4.60B | 2.01B | 9.88B | 3.28B | 4.10B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | 11.09 | 12.91 | 19.87 | 20.52 | 16.40 | 13.22 | 13.15 | 13.02 |
| ROA % | 5.20 | 6.45 | 10.01 | 9.41 | 7.23 | 6.12 | 6.46 | 6.46 |
| ROIC % | 7.35 | 8.74 | 13.13 | 12.37 | 9.55 | 8.08 | 8.14 | 8.18 |
| 5-year avg ROE % | 9.91 | 10.47 | 12.55 | 14.77 | 16.16 | 16.58 | 16.63 | 15.26 |
| EBIT margin % | 16.13 | 18.58 | 24.14 | 23.91 | 19.06 | 17.90 | 19.65 | 19.59 |
| FCF / sales % | 15.54 | 15.84 | 21.15 | 17.31 | 15.39 | 16.16 | 16.95 | 14.12 |
| Current ratio | 1.73 | 1.92 | 2.13 | 1.50 | 1.48 | 1.75 | 1.66 | 1.89 |
| Quick ratio | 1.09 | 1.19 | 1.63 | 1.00 | 1.06 | 1.27 | 1.14 | 1.36 |
| Debt / assets | 68.84 | 59.82 | 62.99 | 85.48 | 78.42 | 74.71 | 63.07 | 73.75 |
| LT debt / equity | 64.23 | 57.54 | 55.37 | 79.26 | 65.74 | 66.99 | 58.61 | 67.13 |
| Interest coverage | 5.89 | 7.02 | 14.07 | 17.49 | 11.79 | 5.58 | 6.06 | 6.15 |
| Revenue CAGR (3Y) % | 12.81 | 11.81 | 15.49 | 17.20 | 20.70 | 9.98 | 3.03 | -0.27 |
| Net income CAGR (3Y) % | 14.16 | 22.27 | 42.03 | 38.02 | 23.43 | -2.03 | -6.40 | -1.19 |
| FCF CAGR (3Y) % | 14.54 | 12.88 | 24.91 | 21.50 | 19.53 | 0.54 | 2.29 | -3.07 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 13.73 | 13.44 | 13.14 | 13.02 | 13.52 | 13.50 |
| ROA % | 6.64 | 6.59 | 6.46 | 6.46 | 6.45 | 6.50 |
| ROIC % | 8.28 | 8.23 | 8.13 | 8.18 | 8.13 | 8.24 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 19.58 | 19.42 | 19.36 | 19.59 | 19.67 | 19.65 |
| FCF / sales % | 15.67 | 14.28 | 13.97 | 14.12 | 14.93 | 15.79 |
| Current ratio | 1.77 | 1.93 | 1.50 | 1.89 | 1.53 | 1.55 |
| Quick ratio | 1.20 | 1.29 | 0.95 | 1.36 | 0.97 | 1.01 |
| Debt / assets | 69.22 | 69.75 | 69.94 | 73.75 | 83.11 | 80.77 |
| LT debt / equity | 63.51 | 65.36 | 62.44 | 67.13 | 77.16 | 74.38 |
| Interest coverage | 6.31 | 6.08 | 6.18 | 6.15 | 6.05 | 6.21 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Laboratory Products and Biopharma Services55.80%
Life Sciences Solutions23.47%
Analytical Instruments15.40%
Specialty Diagnostics10.05%
Quote time 2026-09-04 20:02:14
For reference only, not investment advice.